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Abstract. The case of a 35-year old female patient with a diag-
nosis of metastatic mixed acinar-endocrine carcinoma (MAEC) 
is investigated in the present study. The patient was believed 
to have a well-differentiated neuroendocrine tumor (NET) 
with a high Ki-67 index and uptake on 68Gallium-DOTATOC 
positron emission tomography-computed tomography for 
9 years, and was treated accordingly. The patient had long 
lasting disease control by treatment with sunitinib, and a 
response was observed in numerous lesions with peptide 
receptor radionuclide therapy (PRRT). Following treatment 
for metastatic disease for >4 years, liver transplantation was 
performed, as an exception to normal recommendations, at the 
time of progression of a centrally located liver lesion inducing 
obstructive jaundice. Following transplantation, the diagnosis 
of a Grade 3 NET, as defined by the WHO 2010 classification, 
was challenged and changed to MAEC. MAEC is a rare type of 
tumor of the pancreas, exhibiting endocrine and acinar differ-
entiation. It is difficult to diagnose, often being misidentified 
as acinar cell carcinoma or predominantly as neuroendocrine 
neoplasms. Immunohistochemical labelling provides the 
only evidence for the dual differentiation of neuroendocrine 
(synaptophysin and chromogranin) and acinar (lipase, trypsin 
and chymotrypsin) cell markers. Studies investigating MAECs 
with a clear histopathological diagnosis are scarce, in addi-
tion to evidence of disease behaviour and treatment options. 
It is generally agreed that surgery is the primary treatment in 
patients with resectable tumors. The responses to sunitinib and 
PRRT suggested that treatments considered or developed for 
NETs may be beneficial in MAEC cases.
Introduction
Acinar cell carcinoma (ACC) is a rare pancreatic neoplasm 
that may contain scattered endocrine cells in ≤40% of 
cases (1). In addition, unusual tumors exist in which the 
endocrine component constitutes a significant proportion 
(>25‑30%) of the neoplasm; these tumors are called mixed 
acinar-endocrine carcinoma (MAEC) (2-4). These tumors 
are thought to behave more similarly to typical pancreatic 
ACCs compared with well-differentiated pancreatic endocrine 
neoplasms, and certain authors have suggested they represent 
part of the spectrum of ACCs (3). However, the existence of 
cases with a predominant endocrine tumor cell component 
challenges this notion. MAEC is rare and, thus, evidence on 
disease behaviour and treatment options is scarce. MAECs 
are usually regarded as tumors with a poor prognosis and are 
treated with surgery and/or chemotherapy (4). The diagnosis 
of MAEC remains a challenge; therefore, cases may be under-
reported and misidentified as ACC, solid-pseudopapillary 
neoplasms, neuroendocrine tumors (NETs) or neuroendocrine 
carcinomas (NECs) (1,4). Here, a case of a female with a diag-
nosis of metastatic MAEC is presented. During the course 
of the patient's disease it was believed for 9 years to be a 
well-differentiated NET with a high Ki-67 index, a Grade 3 
(G3) pancreatic neuroendocrine tumor (NET) (5), with uptake 
on 68Gallium-labelled somatostatin analogs (68Ga-SMA)-posi-
tron emission tomography-computed tomography (PET/CT). 
Treatment proposals were provided accordingly. The patient 
had long-lasting disease control by treatment with sunitinib 
and a response was observed in numerous lesions due to 
peptide receptor radionuclide therapy (PRRT). Following the 
last surgery, seven years after initial presentation, the diagnosis 
of G3 NET was challenged and changed to MAEC. Written 
informed consent from the patient was obtained.
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Case report
In August 2007, a 35-year old female underwent an enucle-
ation of a 2.5 cm cystic tumoral lesion located in the head 
of the pancreas. Histopathological examination resulted in 
identification of a NET with a Ki‑67 index of 40%; however, 
diagnosis was later updated to solid-pseudopapillary neoplasm 
as focal β-catenin positivity was revealed. No complementary 
surgery was performed.
In March 2010, a novel lesion was observed in the pancreas, 
along with multiple bilobar liver metastases. The patient 
was expected to undergo a pancreaticoduodenectomy and 
two-stage hepatectomy. The patient underwent the resection of 
the local recurrence of the primary tumor together with the first 
stage of the hepatectomy, with a resection of the metastases in 
the left liver lobe in December 2010. Subsequently, histopa-
thology revealed that the tumor was a well-differentiated NET, 
displaying a higher than usual Ki‑67 index (40%).
Re‑evaluation in January 2011 revealed the presence of 
novel liver lesions, indicating that a repeat hepatectomy would 
be futile (Fig. 1). Despite the high Ki-67 index and the short 
period until relapse, treatment with sunitinib was selected 
rather than chemotherapy, as the tumor did not demonstrate 
the morphology of poorly differentiated NEC. The lesions 
remained stable on 3-monthly interval 18FDG-PET CT 
(Siemens Biograph mCT 20; Siemens AG, Munich, Germany) 
during 17 months of sunitinib treatment (Fig. 2). The dose of 
sunitinib was reduced from 37.5 to 25 mg daily from May 2012 
onwards, due to the emergence of hand-foot skin reaction. 
During treatment with sunitinib a 68Ga-Dotatoc PET-CT was 
performed in April 2012, which demonstrated uptake, and the 
patient was then referred for PRRT; however, treatment was 
denied due to the high proliferation index.
In June 2012, chemotherapy supplemented with cisplatin 
and etoposide was initiated due to progression of the disease 
(Fig. 3). The chemotherapy was moderately tolerated by the 
patient and stopped in February 2013 when the disease was 
stable following three cycles of treatment. In September 2013, 
the patient was referred and accepted for PRRT (Fig. 4A and B). 
The patient underwent 3/4 planned treatment sessions; delays 
were often experienced due to bone marrow toxicity. Therapy 
with PRRT was completed in January 2014 and a good 
response in all but one lesion was observed (Fig. 4C). This 
lesion demonstrated a high metabolic activity on 18Fludeoxy-
glucose (18F-FDG) PET/CT and fine needle aspiration revealed 
a Ki‑67 index of 40%.
In April 2014, therapy with temozolomide-capecitabine 
was initiated, and fast progression was observed. The patient 
developed jaundice due to biliary obstruction at the hilus of 
the liver (Fig. 5). It was technically impossible to perform 
adequate biliary internal drainage. External drainage was 
performed, leading to amelioration, but no resolution of the 
jaundice was achieved, limiting the treatment options.
At this time, the patient had had a diagnosis of meta-
static G3 NET for four years, and the disease had been well 
controlled for long periods previously. Alternative treatment 
options could have been discussed again if the level of bilirubin 
was improved. During the clinical course and disease evolu-
tion, despite the high Ki-67 index, it was agreed to perform 
a liver transplantation in the patient using a marginal graft. 
A suitable graft from a 68-year old brain-dead female donor 
with a history of 15 years of breast cancer became available, 
leading to a successful transplantation in October 2014. In 
the explant liver, all lesions had similar pathological features 
and a diagnosis of a well-differentiated NET with Ki-67 
index ≤40%. Immunosuppression was based on tacrolimus 
and mycophenolate mofetil, with a switch to sirolimus from 
tacrolimus after four weeks. Restaging in March 2015 revealed 
no signs of tumor recurrence; however, a novel re‑evaluation 
in October 2015, one year following transplantation, identi-
fied numerous metastatic long nodules, demonstrating uptake 
on 68Ga-Dotatoc PET-CT (Fig. 6). Therapy with octreotide 
analogues was initiated. The patient is currently (January 
2017) asymptomatic and has a good quality of life.
Review of the pathology specimens at this time challenged 
the diagnosis. Following revision of all previous resection 
specimens and the inclusion of markers for pancreatic lipase, 
trypsin and chymotrypsin, a diagnosis of MAEC was deter-
mined (Fig. 7).
Discussion
MAEC are rare tumors of the pancreas. They are malignant 
epithelial neoplasms exhibiting both endocrine and acinar 
differentiation. (2) By arbitrary definition, each component 
must compromise ≥25% of the neoplasm for a diagnosis of 
MAEC (2,4). Immunohistochemical labelling is performed 
in order to diagnose the disease. This revealed regions with 
acinar differentiation displaying positivity for lipase, trypsin 
and/or chymotrypsin, and regions with endocrine differ-
entiation demonstrated positivity for synaptophysin and 
chromogranin (2-4).
MAEC is challenging for pathologists to diagnose and 
easily confused with ACC, solid pseudopapillary neoplasms 
and predominantly with neuroendocrine neoplasms (1,4). In 
the majority of cases there is a close intermingling of the acinar 
and endocrine component without clear segregation of the two 
cell types, thus it is not possible to identify with certainty the 
two lines of differentiation by routine histology (2). Immuno-
histochemical labelling for neuroendocrine and acinar cell 
markers provides the only evidence for dual differentiation. 
In contrast to neuroendocrine immunohistochemical markers, 
markers for pancreatic enzymes are not widely available 
outside of large hospitals, including at the time of diagnosis of 
the patient in the present case. In order to achieve the correct 
diagnosis, referral to a specialized department with access to 
these markers is indicated.
MAEC is thought to behave more akin to typical pancreatic 
ACCs, compared with well-differentiated pancreatic endocrine 
neoplasms (3,4). Pancreatic ACC is commonly treated in the 
same way as adenocarcinomas, although the disease may have 
a more indolent course, as suggested by increased survival 
rates demonstrated in the Surveillance, Epidemiology, and End 
Results Programme database for unresected (5-year survival 
rate, 22%) and resected ACC (5‑year survival rate, 72%) (1). In 
the present study analysis, it is confirmed that the diagnosis of 
ACC can be difficult to make and that incorrect classification 
of NETs and MAEC may favourably bias the survival rate.
Reports on MAECs with a clear histopathological diag-
nosis are scarce, in addition to evidence on disease behaviour 
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and treatment options. Recently, a review on ~30 presented 
cases in literature was published (4). The general consensus 
is that surgery is the primary treatment method for patients 
with resectable tumors, and reports of patients benefiting from 
tumor debulking surgery have been revealed (4). The median 
overall survival time following surgery was indicated to be 
~12 months; however, this assumption was made based on a 
small number of patients with various tumor loads and lengths 
of follow-up (4). The patient in the present case relapsed 
2.5 years following resection of the primary tumor and exhib-
ited local recurrence in the pancreas and liver metastases.
To the best of our knowledge, no previous studies have 
been published investigating the use of functional imaging 
techniques in MAEC, although in a certain case report the 
Figure 1. 18Fludeoxyglucose PET-CT scan at the commencement of sunitinib treatment. (A and B) The bright spots indicate liver metastases with high 
18FDG-uptake (arrow) on combined PET-CT-scan in 2 cross-sectional images. (C) high 18FDG-uptake on PET-scan in 1 coronal plane image. (D) liver metas-
tases on CT scan in 1 cross-sectional image. PET-CT, positron emission tomography-computed tomography.
Figure 2. 18F-FDG PET-CT in March 2012. (A) Metabolic response (no 18FDG-uptake) on PET scan in 1 coronal plane image. (B) liver metastases on CT scan 
in 1 cross-sectional image. An increased volume of the liver metastases with minimal 18F-FDG uptake on PET suggests a metabolic response with necrosis. 
18F-FDG, 18Fludeoxyglucose; PET‑CT, positron emission tomography‑computed tomography.
Figure 3. Computed tomography scan at the commencement of treatment 
with platinum-based chemotherapy illustrating liver metastases.
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use of an octreoscan following resection was discussed (6). 
Patients with neuroendocrine neoplasms may have lesions with 
various uptakes of 18F-FDG PET/CT and 68Ga-SMA PET/CT. 
Typically there is a higher uptake of 68Ga-SMA in well differ-
entiated NETs compared with in poorly differentiated NECs, 
and a higher uptake of 18F-FDG in poorly differentiated NEC 
compared with in well differentiated NETs (7,8). Particularly 
in patients with multiple metastases, tracer uptake can be vari-
able at different lesion sites (8). Furthermore, certain lesions 
within the same patient may be apparent on 68Ga-SMA PET/CT 
and not on 18F-FDG PET/CT, or vice versa: this reflects tumor 
heterogeneity (8). This case study presented a patient who had 
distinct lesions on 68Ga-Dotatoc PET-CT, in accordance with 
the histopathological diagnosis of a component of well-differ-
entiated NET. The patient also exhibited uptake on 18F-FDG 
PET/CT in certain lesions, which may be associated with the 
acinar cell component.
In NETs, an higher uptake on functional imaging scans 
has been suggested to be associated with increased of overall 
survival, and treatment decisions have been challenged based 
on the results of functional scans (7,9-11). Treatment decisions 
in tumor‑node‑metastasis stage IV NETs were previously 
determined based on the grade of differentiation, prior to 
the introduction of the Rindi grading system in 2006 (12), 
which was later integrated into the World Health Organisa-
tion (WHO) 2010 classification system (5). It is becoming 
more accepted that the current WHO 2010 G3 category 
includes neuroendocrine neoplasms of two distinct types: 
A highly proliferative group of well-differentiated NETs 
(WD‑NETs) and the poorly‑differentiated NECs, divided 
into small cell and large cell NECs (5,12-17). The pattern of 
uptake in functional imaging provided evidence supporting 
the decision to administer the patient in the present study, 
who was thought to have a diagnosis of a well-differentiated 
G3 neuroendocrine neoplasm with a Ki‑67 index of 40% 
maximum, chemotherapy (cisplatin-etoposide and temo-
zolomide-capecitabine), as recommended for NEC, and a 
tyrosine kinase inhibitor (TKI), sunitinib, PRRT and liver 
transplantation (5,12-17).
For a rare disease such as MAEC, it is not possible to 
conduct trials for robust evidence of therapeutic effects 
and case reports are important sources of information. The 
patient in the present study had stable disease with treat-
ment of sunitinib for 17 months, and no objective response to 
cisplatin-etoposide, but control of the disease was obtained 
for 15 months. Conversely, the response to PRRT was clearly 
documented in all but one lesion; however, time to tumor 
progression (TTP) was only four months due to one rapidly 
progressive lesion. It was observed that the combination of 
temozolomide-capecitabine in the fourth line of treatment 
did not demonstrate any therapeutic benefit to the patient; 
however, the subsequent therapeutic interventions may have 
altered the properties of the tumor. Selection pressure may 
have exhibited an impact on slower growing parts of the 
tumor, leaving more aggressive cells behind. However, the 
tumor lesions in the explant liver were extensively sampled 
and were not considered to differ histopathologically. 
More specifically, the rapidly progressive lesion was not 
revealed to have a higher Ki-67 index or a differing cell popu-
lation.
Upon revision at one year, performed for academic reasons, 
and the application of immunohistochemical markers for 
pancreatic enzymes, the diagnosis was changed to an MAEC. 
Revision of older tissue specimens concurred with this finding. 
Figure 5. 18Fludeoxyglucose positron emission tomography-computed 
tomography in April 2014 illustrating progression of the biggest liver metas-
tasis leading to biliary obstruction.
Figure 4. (A) 68Gallium-DOTATOC positron emission tomography-computed 
tomography prior to PRRT commencement: Liver metastases demonstrating 
high uptake of 68Gallium-DOTATOC (September 2013). (B) CT scan 
prior to PRRT commencement demonstrating the same liver metastases 
(September 2013). (C) CT scan following PRRT demonstrating one progres-
sive metastasis and response in the lesions that exhibited a high uptake of 
68Gallium‑DOTATOC (January 2014). CT, computed tomography; PRRT, 
peptide receptor radionuclide therapy.
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Liver transplantation is not a standard treatment in neuroendo-
crine neoplasms with a high Ki-67 index, and was performed 
exceptionally as the only lifesaving option at the time of 
progression of a centrally located liver lesion that had induced 
obstructive jaundice in a young patient treated for metastatic 
disease for >4 years. Relapse occurred 13 months following 
this and the novel lesions again demonstrated uptake on 
68Ga-Dotatoc PET-CT, suggesting a component of well-differ-
entiated NET. The absence of fast recurrence following 
this surgical intervention in spite of therapy with immune 
suppression may add to the suggestion that surgery should be 
performed when possible in patients with MAEC (1,4).
The response to the active sunitinib and PRRT treat-
ments suggested that treatment of the endocrine component 
within the MAEC in addition to surgery may be beneficial. 
In conclusion, a case of MAEC of the pancreas that demon-
strated uptake on 68Ga-Dotatoc PET-CT was presented, 
challenging the suggestion of using these active treatments 
for the endocrine component of the tumor. The majority of 
the lesions responded to PRRT and a durable disease control 
was suggested with TKIs and chemotherapy. However, the 
present case report also revealed that surgical options must 
be considered in MAEC.
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